Literature DB >> 19268740

Value of medical therapy in patients >80 years of age with heart failure and preserved ejection fraction.

Faramarz Tehrani1, Anita Phan, Christopher V Chien, Ryan P Morrissey, Asim M Rafique, Ernst R Schwarz.   

Abstract

Heart failure (HF) with preserved ejection fraction (EF) has a high prevalence in the geriatric population, and this cohort may be at risk of complications caused by polypharmacy. Effects of commonly used cardiac medications on long-term survival of patients >80 years with HF and preserved left ventricular EF were assessed. One hundred forty-two patients were evaluated. During a 5-year follow-up, 98 patients died (69%). There were no significant differences in baseline parameters in patients who died compared with those who survived at 5 years. None of the drug therapies appeared to make a significant difference in long-term survival, including beta blockers (p = 0.89), angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (p = 0.91), calcium channel blockers (p = 0.69), diuretics (p = 0.30), digoxin (p = 0.22), and statins (p = 0.32). In conclusion, based on the present data, it appears that use of certain common cardiac medications may not be associated with a significant effect on long-term survival in octogenarians with HF and preserved EF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19268740     DOI: 10.1016/j.amjcard.2008.11.047

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

Review 1.  Aging and heart failure: changing demographics and implications for therapy in the elderly.

Authors:  Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2010-09       Impact factor: 4.214

Review 2.  STEMI and heart failure in the elderly: role of adverse remodeling.

Authors:  Anwar Jelani; Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2010-09       Impact factor: 4.214

Review 3.  Heart failure with preserved ejection fraction in the elderly: scope of the problem.

Authors:  Ken Kaila; Mark J Haykowsky; Richard B Thompson; D Ian Paterson
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

Review 4.  Pharmacological Treatment of Heart Failure with Preserved Ejection Fraction.

Authors:  Kazuhiro Yamamoto
Journal:  Yonago Acta Med       Date:  2017-06-26       Impact factor: 1.641

Review 5.  Heart failure management in the elderly - a public health challenge.

Authors:  Natasa Cvetinovic; Goran Loncar; Jerneja Farkas
Journal:  Wien Klin Wochenschr       Date:  2016-11-29       Impact factor: 1.704

Review 6.  Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis.

Authors:  Chirag Bavishi; Saurav Chatterjee; Sameer Ather; Dipen Patel; Franz H Messerli
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

Review 7.  Treatment for chronic heart failure in the elderly: current practice and problems.

Authors:  Pasquale Abete; Gianluca Testa; David Della-Morte; Gaetano Gargiulo; Gianluigi Galizia; Domenico de Santis; Antonio Magliocca; Claudia Basile; Francesco Cacciatore
Journal:  Heart Fail Rev       Date:  2013-07       Impact factor: 4.214

Review 8.  Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly.

Authors:  Bodh I Jugdutt
Journal:  Clin Interv Aging       Date:  2010-12-03       Impact factor: 4.458

9.  Cardiorenal syndrome caused by heart failure with preserved ejection fraction.

Authors:  Chiara Lazzeri; Serafina Valente; Roberto Tarquini; Gian Franco Gensini
Journal:  Int J Nephrol       Date:  2011-02-07

10.  Levosimendan Improves Clinical Outcomes of Refractory Heart Failure in Elderly Chinese Patients.

Authors:  Dengqing Zhang; Yuanqing Yao; Jun Qian; Jing Huang
Journal:  Med Sci Monit       Date:  2015-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.